Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;77(12):1937-1938.
doi: 10.1007/s00228-021-03197-8. Epub 2021 Aug 7.

Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal

Beatrice Bouhanick  1 , François Montastruc  2 , Samuel Tessier  3 , Clara Brusq  4 , Vanina Bongard  4 , Jean-Michel Senard  3 , Jean-Louis Montastruc  5 , Fabrice Herin  6
Affiliations

Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal

Beatrice Bouhanick et al. Eur J Clin Pharmacol. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Meylan S, Livio F, Foerster M, Genoud PJ, Marguet M, Wuerzner G, on behalf of the CHUV COVID Vaccination Center Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension. 2021;77:e56–e57. doi: 10.1161/HYPERTENSIONAHA.121.17316. - DOI - PMC - PubMed
    1. Moore N, Berdaï D, Blin P, Droz C. Pharmacovigilance - the next chapter. Therapie. 2019;74:557–567. doi: 10.1016/j.therap.2019.09.004. - DOI - PubMed
    1. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905–908. doi: 10.1111/j.1365-2125.2011.04037.x. - DOI - PMC - PubMed
    1. Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74:225–232. doi: 10.1016/j.therap.2019.01.006. - DOI - PubMed
    1. Pierfitte C, Bégaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47:329–331. doi: 10.1046/j.1365-2125.1999.00881.x. - DOI - PMC - PubMed

Substances